News Novartis two for two as ianalumab scores again Novartis' ianalumab has delivered another win in primary immune thrombocytopenia, its second win in autoimmune diseases in 24 hours.
News MorphoSys takeover delivers phase 3 win for Novartis A drug for autoimmune disease Sjögren's syndrome, claimed by Novartis when it bought MorphoSys, could soon be filed for approval.
News More pharma M&A as Novartis snaps up MorphoSys for $2.9bn Novartis is continuing a streak of pipeline-building deals with an agreement to buy Germany’s MorphoSys in a transaction that values the cancer-focused biotech at €2.7 billion (around
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.